Ultime notizie per Cargo Therapeutics (NASDAQ:CRGX) Azioni

Cargo Therapeutics

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Cargo Therapeutics Inc

<p>Kevin O&#8217;Leary, known for his <a href="https://www.benzinga.com/startups/24/11/41781866/kevin-oleary-claims-you-have-to-work-25-hours-a-day-for-him-business-is-simple-you-either-make-money">straightforward views on business and investing</a>, recently weighed in on the Democratic Party's trajectory during an <a href="https://www.youtube.com/watch?v=OJL6LYMQfeo">appearance</a> on Fox News. And his take might surprise you – he thinks losing the upcoming election could be the best thing that happens to the Democrats.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Losing tonight is the best thing that could have happened to the Democratic Party. They circumvented democracy by anointing a candidate and suggested policies that went against the American dream. Losing the election should reset and reboot the Democratic party back to the center <a href="https://t.co/CUFQ9thaR7">pic.twitter.com/CUFQ9thaR7</a></p>
<p>&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1854139515452916077?ref_src=twsrc%5Etfw">November 6, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"><strong> </strong><strong>here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</strong></a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"><strong> </strong><strong>You can still get 4,000 of its pre-IPO shares for just $1,000</strong></a></strong></li>
</ul>
<p>O&#8217;Leary compared the current situation to a Super Bowl game, calling the presidential race &#8220;the Super Bowl of global politics.&#8221; <a href="https://www.benzinga.com/news/24/08/40541886/kevin-oleary-cautions-democrats-about-kamala-harris-they-did-the-same-thing-with-hillary-clinton">He criticized the Democrats</a> for &#8220;anointing&#8221; a candidate instead of allowing a proper process. &#8220;You don't bring a quarterback in that's never, ever, ever won any game anywhere,&#8221; he said, pointing out that President Biden, their &#8220;quarterback,&#8221; is currently struggling. Yet, the party didn't run a proper selection process for an alternative.</p>
<p>In his view, a loss would force the Democrats to &#8220;reset and reboot and get that party back to the center.&#8221; He argued that influential figures like Chuck Schumer, <a href="https://www.benzinga.com/startups/24/11/41714647/nancy-pelosi-claims-trump-will-double-down-on-tariffs-and-benefits-for-donors-she-warns-these-moves">Nancy Pelosi</a> and even Barack Obama won't be able to exert the same level of control four years from now, which could be a positive shift for the party and the country.</p>
<p><strong>Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></p>
<p>O&#8217;Leary also touched on some policy issues that he feels are misaligned with the American dream, particularly those concerning economic freedom. As an investor, he said he has to <a href="https://www.benzinga.com/news/24/09/40866546/as-an-investor-i-have-to-work-with-whoever-is-in-the-white-house-kevin-oleary-remarks-having-receive">work with whoever is in the White House</a>, but he can&#8217;t ignore policies that harm the core of what makes America unique. &#8220;All I do is work with entrepreneurs that want to build businesses,&#8221; he said, calling out two major policies: taxing unrealized capital gains and implementing price controls.</p>
<p>&#8220;That&#8217;s not America,&#8221; O&#8217;Leary declared. He clarified that taxing unrealized capital gains – requiring individuals to pay taxes on investments that haven&#8217;t even been sold – violates core American principles.&nbsp;</p>
<p><strong>See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"><strong> </strong><strong>you can become an investor for $0.80 per share today.</strong></a></strong></p>
<p>He also criticized the idea of a higher corporate tax rate, which he believes would make the U.S. less competitive globally. &#8220;An 18% tax rate takes us to the bottom quartile of competition – that&#8217;s bad.&#8221; He believes measures like these deter innovation and investment, which are critical to economic expansion.</p>
<p>Despite his strong words, O&#8217;Leary made it clear that he respects <a href="https://www.benzinga.com/general/politics/24/11/41790636/kamala-harris-concedes-calls-for-unity-commitment-to-democracy">Vice President Kamala Harris</a> for her efforts in reaching where she is today. He thinks a defeat could give the party a much-needed chance to reconsider its course and return to emphasizing policies promoting development and opportunity.</p>
<p>&#8220;This could be great for America,&#8221; O&#8217;Leary said, stressing that a more centrist, pragmatic Democratic Party would benefit the entire country.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"><strong> </strong><strong>invest today with $1,000 for just $0.25/share</strong></a></strong></li>
<li><strong>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai"><strong>Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</strong></a></strong></li>
</ul>


Startups

Kevin O'Leary Says Losing Could Be The Greatest Moment For Democrats. Unrealized Capital Gains Taxes And Price Controls? 'Not America'

<p>Barclays  analyst Ryan Macwilliams   maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Equal-Weight and raises the price target from $500 to $650.</p>


News

Price Target

Analyst Ratings

HUBS

Barclays Maintains Equal-Weight on HubSpot, Raises Price Target to $650

<p>Northland Capital Markets  analyst Mike Grondahl   maintains OppFi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) with a Outperform and raises the price target from $6 to $8.</p>


OPFI

Northland Capital Markets Maintains Outperform on OppFi, Raises Price Target to $8

<p>Barclays  analyst Brandt Montour   maintains Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) with a Overweight and raises the price target from $40 to $44.</p>


Barclays Maintains Overweight on Hilton Grand Vacations, Raises Price Target to $44

<p>Barclays  analyst David Anderson   maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Overweight and lowers the price target from $47 to $43.</p>


Barclays Maintains Overweight on Halliburton, Lowers Price Target to $43

Management

IMXI

Earlier Reported, International Money Express Believes That Current Market Valuation Does Not Fully Capture The Co's Performance, Positive Cash, Intrinsic Value Or Growth Potential. Committed To Acting In The Best Interest Of Shareholders, Initiating A Process To Assess Strategic Initiatives, Which Could Include Among Others, A Potential Sale In A Private Transaction

WIIM

Trump Media & Technology shares are trading higher following President-elect Donald Trump's election victory. Trump denied rumors of a potential share sale in a post on Truth Social.

<p>Barclays  analyst Saket Kalia   maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Equal-Weight and raises the price target from $85 to $95.</p>


FTNT

Barclays Maintains Equal-Weight on Fortinet, Raises Price Target to $95

LITE

Lumentum Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates.

<p>Barclays  analyst Gena Wang   maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Overweight and lowers the price target from $125 to $111.</p>


MRNA

Barclays Maintains Overweight on Moderna, Lowers Price Target to $111

<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%">
<p>On Thursday, <strong>Moderna Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported third-quarter revenue of $1.83 billion, beating the <a href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024">consensus of $1.25 billion</a>.</p>
<p>The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.</p>
<p><strong>BofA Securities</strong> notes that Moderna&#8217;s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company&#8217;s respiratory vaccine lineup, as well as new concerns related to Trump and Kennedy&#8217;s positions on vaccines.</p>
<p>The analyst has reduced the <a href="https://www.benzinga.com/quote/MRNA/analyst-ratings">price target from $110 to $90</a>, adjusting for a higher discount rate (9% instead of 7%) based on updated commercial risk expectations, lower sales forecasts for COVID-19 and RSV vaccines, and reduced net cash. The analyst maintained a Neutral rating on Moderna.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology">Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology</a></strong></p>
<p><strong>Leerink Partners</strong> notes the earnings update didn&#8217;t improve the negative outlook for COVID and RSV, and the revenue beat, driven by excess inventory, pointed to weak earnings quality.</p>
<p>The company faces challenges from declining COVID demand and losing market share to <strong>Pfizer Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), which could affect Moderna's ability to clear excess inventory and raise concerns about potential write-downs in the fourth quarter of 2024.</p>
<p>Leerink has lowered the price target from $46 to $38, with an Underperform rating.</p>
<p><strong>Oppenheimer </strong>remains optimistic about the long-term potential of Moderna's RSV vaccine, mRESVIA growth. &#8220;We think MRNA is well-positioned to extend the mRESVIA label into high-risk adults 18-59, filing an sBLA with PRV by YE24,&#8221; the analyst writes, and maintains the Perform rating.</p>
<p>The analyst notes mRESVIA launch will take longer than expected but still considers it an undervalued asset, particularly with its upcoming label extension.</p>
<p>The analyst also adds, &#8220;We are impressed by MRNA&#8217;s progress toward opex optimization and believe such efficiency could invite a larger upside for its upcoming pipeline launches.&#8221;</p>
<p>The company expects the cost of sales to be 40-45% of product sales for the year (previously 40-50%), with R&amp;D expenses anticipated to be $4.6 billion—<a href="https://www.benzinga.com/calendars/guidance">$4.7 billion (previously $4.8 billion).</a></p>
<p><strong>Price Action: </strong>MRNA stock is down 6.33% at $47.10 at last check Friday.</p>
<p><em>Photo by Lutsenko_Oleksandr on Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report"><strong>Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report</strong></a></li>
</ul>
</div>
</div>


Analyst Color

Biotech

Equities

Health Care

Reiteration

Trading Ideas

General

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Blackstone</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Blackstone.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 42% bullish and 28%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $416,405, and 12 are calls, for a total amount of $768,583.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $185.0 for Blackstone, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Blackstone options trades today is 772.08 with a total volume of 1,075.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Blackstone's big money trades within a strike price range of $120.0 to $185.0 over the last 30 days.</p>
<h3>Blackstone Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731091632_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.95</td>
<td>$7.7</td>
<td>$9.0</td>
<td>$130.00</td>
<td>$360.0K</td>
<td>7</td>
<td align="right">400</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$8.55</td>
<td>$7.95</td>
<td>$8.55</td>
<td>$170.00</td>
<td>$203.4K</td>
<td>1.6K</td>
<td align="right">239</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$42.0</td>
<td>$42.0</td>
<td>$42.0</td>
<td>$140.00</td>
<td>$142.8K</td>
<td>958</td>
<td align="right">34</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$51.85</td>
<td>$47.7</td>
<td>$49.9</td>
<td>$145.00</td>
<td>$74.8K</td>
<td>174</td>
<td align="right">15</td>
</tr>
<tr>
<td>BX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$19.45</td>
<td>$18.85</td>
<td>$19.45</td>
<td>$185.00</td>
<td>$56.4K</td>
<td>0</td>
<td align="right">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Blackstone</h3>
<p>Blackstone is the world's largest alternative-asset manager with $1.076 trillion in total asset under management, including $808.7 billion in fee-earning assets under management, at the end of June 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 28% of base management fees), real estate (37% and 42%), credit and insurance (29% and 23%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).</p>
<p>In light of the recent options history for Blackstone, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Blackstone</h3>
<ul>
<li>With a trading volume of 1,086,978, the price of BX is up by 0.67%, reaching $177.48.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 76 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Blackstone</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $151.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Blackstone with a target price of $155.<br />
&#x2A; An analyst from TD Cowen has decided to maintain their Hold rating on Blackstone, which currently sits at a price target of $149.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Blackstone, which currently sits at a price target of $170.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Blackstone with a target price of $134.<br />
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Blackstone, maintaining a target price of $150. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Blackstone, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

A Closer Look at Blackstone's Options Market Dynamics

<p>Financial giants have made a conspicuous bullish move on Trade Desk. Our analysis of options history for Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) revealed 41 unusual trades.</p>
<p>Delving into the details, we found 46% of traders were bullish, while 43% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $587,459, and 29 were calls, valued at $2,049,304.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $148.0 for Trade Desk during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Trade Desk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Trade Desk's significant trades, within a strike price range of $50.0 to $148.0, over the past month.</p>
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731091627_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.7</td>
<td>$15.1</td>
<td>$16.7</td>
<td>$140.00</td>
<td>$334.0K</td>
<td>1.0K</td>
<td align="right">300</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.7</td>
<td>$17.9</td>
<td>$17.9</td>
<td>$140.00</td>
<td>$214.8K</td>
<td>1.0K</td>
<td align="right">428</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$19.55</td>
<td>$19.55</td>
<td>$19.55</td>
<td>$139.00</td>
<td>$146.6K</td>
<td>225</td>
<td align="right">75</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$65.1</td>
<td>$62.65</td>
<td>$64.1</td>
<td>$60.00</td>
<td>$128.2K</td>
<td>296</td>
<td align="right">76</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$66.35</td>
<td>$63.25</td>
<td>$64.5</td>
<td>$60.00</td>
<td>$103.2K</td>
<td>296</td>
<td align="right">46</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>Having examined the options trading patterns of Trade Desk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Trade Desk</h3>
<ul>
<li>With a volume of 10,134,362, the price of TTD is down -5.25% at $125.58. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 97 days.</li>
</ul>
<h3>Professional Analyst Ratings for Trade Desk</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $140.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Trade Desk, maintaining a target price of $150.<br />
&#x2A; Reflecting concerns, an analyst from Wells Fargo lowers its rating to Overweight with a new price target of $150.<br />
&#x2A; An analyst from Wedbush persists with their Outperform rating on Trade Desk, maintaining a target price of $135.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Trade Desk, which currently sits at a price target of $135.<br />
&#x2A; Maintaining their stance, an analyst from Macquarie continues to hold a Outperform rating for Trade Desk, targeting a price of $130. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Trade Desk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On Trade Desk

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Redfin</strong>.</p>
<p>Looking at options history for Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) we detected 15 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 26% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $159,160 and 13, calls, for a total amount of $2,594,635.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $20.0 for Redfin over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Redfin's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Redfin's substantial trades, within a strike price spectrum from $5.0 to $20.0 over the preceding 30 days.</p>
<h3>Redfin Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731091622_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.0</td>
<td>$1.85</td>
<td>$1.9</td>
<td>$8.00</td>
<td>$1.6M</td>
<td>1.7K</td>
<td>8.5K</td>
</tr>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.8</td>
<td>$5.0</td>
<td>$5.75</td>
<td>$5.00</td>
<td>$287.5K</td>
<td>7.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.7</td>
<td>$4.3</td>
<td>$5.66</td>
<td>$5.00</td>
<td>$283.0K</td>
<td>7.2K</td>
<td>1.5K</td>
</tr>
<tr>
<td>RDFN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.85</td>
<td>$0.75</td>
<td>$0.75</td>
<td>$10.00</td>
<td>$120.1K</td>
<td>3.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.3</td>
<td>$2.2</td>
<td>$2.25</td>
<td>$10.00</td>
<td>$113.7K</td>
<td>135</td>
<td>831</td>
</tr>
</tbody>
</table>
</p>
<h3>About Redfin</h3>
<p>Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.</p>
<p>After a thorough review of the options trading surrounding Redfin, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Redfin</h3>
<ul>
<li>With a volume of 13,061,904, the price of RDFN is down -16.84% at $9.53. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 109 days.</li>
</ul>
<h3>What Analysts Are Saying About Redfin</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $10.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wedbush persists with their Neutral rating on Redfin, maintaining a target price of $10.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Redfin, targeting a price of $11. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Redfin with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RDFN

Redfin's Options: A Look at What the Big Money is Thinking

<p>Northland Capital Markets  analyst Tim Savageaux   maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Outperform and raises the price target from $18 to $25.</p>


AAOI

Northland Capital Markets Maintains Outperform on Applied Optoelectronics, Raises Price Target to $25

PARA

Paramount Global shares are trading lower following mixed Q3 results.

<p>Northland Capital Markets  analyst Tim Savageaux   maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Market Perform and raises the price target from $45 to $60.</p>


Northland Capital Markets Maintains Market Perform on Lumentum Holdings, Raises Price Target to $60

<p>Northland Capital Markets  analyst Mike Grondahl   maintains MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) with a Outperform and raises the price target from $60 to $80.</p>


Northland Capital Markets Maintains Outperform on MoneyLion, Raises Price Target to $80

<p>Northland Capital Markets  analyst Greg Gibas   maintains Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) with a Market Perform and lowers the price target from $3 to $2.</p>


NRDY

Northland Capital Markets Maintains Market Perform on Nerdy, Lowers Price Target to $2

<p>Northland Capital Markets  analyst Mike Grondahl   maintains Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Outperform and raises the price target from $185 to $300.</p>


SEZL

Northland Capital Markets Maintains Outperform on Sezzle, Raises Price Target to $300

CARGO Therapeutics, Inc. (CRGX) has received a new Buy rating, initiated by Piper Sandler analyst, Biren Amin. Biren Amin has given his Buy rating ...

CARGO Therapeutics' Promising Pipeline and Market Potential Justify Buy Rating

CARGO Therapeutics, Inc. (CRGX) has received a new Buy rating, initiated by Chardan Capital analyst, Geulah Livshits. Geulah Livshits has given his...

Buy Rating Affirmed for CARGO Therapeutics on Promising CAR-T Advancements and Strategic Positioning

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report), with a ...

CARGO Therapeutics: Strong Buy on Robust Financials and Promising Clinical Trials

CARGO Therapeutics GAAP EPS of -$1.02

In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report)...

Truist Financial Reaffirms Their Buy Rating on CARGO Therapeutics, Inc. (CRGX)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Cargo Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/crgx-stock-quote/"><strong>CRGX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Cargo Therapeutics reported earnings per share of -$1.02. This was above the analyst estimate for EPS of -$1.06.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/crgx-stock-earnings-cargo-therapeutics-for-q2-of-2024/">CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024

Piper Sandler analyst Biren Amin maintained a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a price target of $34.0...

Piper Sandler Reaffirms Their Buy Rating on CARGO Therapeutics, Inc. (CRGX)

In a report released today, Brian Cheng from J.P. Morgan reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report), with a price...

Firi-cel's Promising Outlook and Undervalued Potential Drive Buy Rating for CARGO Therapeutics

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of Hemat...

Cargo Therapeutics announces ASH 2024 abstract on CRG-023

CRGX

Earnings

Press Releases

CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

CARGO Therapeutics to Participate in Upcoming Investor Conferences

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet

CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity

Comments

Cargo Therapeutics

Notizie

Ultime notizie per Cargo Therapeutics (NASDAQ:CRGX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO